Artwork

内容由Health Affairs提供。所有播客内容(包括剧集、图形和播客描述)均由 Health Affairs 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!

Scott Howell on the Very Large Costs of Drug Utilization Management

33:02
 
分享
 

Manage episode 300612141 series 2818636
内容由Health Affairs提供。所有播客内容(包括剧集、图形和播客描述)均由 Health Affairs 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

Learn more about academic opportunities in Health Policy and Law at UCSF and UC Law San Francisco.


While estimates vary, spending on prescription drugs in the United States exceeds $500 billion per year. This makes drug prices a perennial health policy topic.

In this context, payers and manufacturers are in a constant battle. Manufacturers seek to expand their market while payers attempt to use their leverage to negotiate lower drug prices. Often, patients and clinicians are caught in the middle and left to navigate increasingly complex pharmaceutical insurance benefit design, tiered formularies, drug rebates, and drug coupon programs.

On today's A Health Podyssey, Scott Howell, chief strategy officer of US pharmaceuticals at Novartis Pharmaceuticals, joins Health Affairs Editor-in-Chief Alan Weil to discuss how much the United States health system spends on drug utilization management.

Howell and co-authors published a paper in the August 2021 issue of Health Affairs exploring the growing burden of drug utilization management and seeking to quantify its financial cost.
They found combined costs shared among payers, manufacturers, physicians, and patients totaling almost a hundred billion dollars per year.

Order the August 2021 issue.

Subscribe: RSS | Apple Podcasts | Spotify | Stitcher | Google Podcasts

  continue reading

174集单集

Artwork
icon分享
 
Manage episode 300612141 series 2818636
内容由Health Affairs提供。所有播客内容(包括剧集、图形和播客描述)均由 Health Affairs 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

Learn more about academic opportunities in Health Policy and Law at UCSF and UC Law San Francisco.


While estimates vary, spending on prescription drugs in the United States exceeds $500 billion per year. This makes drug prices a perennial health policy topic.

In this context, payers and manufacturers are in a constant battle. Manufacturers seek to expand their market while payers attempt to use their leverage to negotiate lower drug prices. Often, patients and clinicians are caught in the middle and left to navigate increasingly complex pharmaceutical insurance benefit design, tiered formularies, drug rebates, and drug coupon programs.

On today's A Health Podyssey, Scott Howell, chief strategy officer of US pharmaceuticals at Novartis Pharmaceuticals, joins Health Affairs Editor-in-Chief Alan Weil to discuss how much the United States health system spends on drug utilization management.

Howell and co-authors published a paper in the August 2021 issue of Health Affairs exploring the growing burden of drug utilization management and seeking to quantify its financial cost.
They found combined costs shared among payers, manufacturers, physicians, and patients totaling almost a hundred billion dollars per year.

Order the August 2021 issue.

Subscribe: RSS | Apple Podcasts | Spotify | Stitcher | Google Podcasts

  continue reading

174集单集

所有剧集

×
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

快速参考指南